Primary Sjögren's syndrome at a glance today

Joint Bone Spine

Volumn 82, Issue 2, 2015, Pages 75-76

  Youinou, Pierre ^a   Pers, Jacques Olivier ^a  

^a Universite de Brest   (France)

Author keywords

Sj gren's syndrome

Indexed keywords

ABATACEPT; AUTOANTIBODY; B CELL ACTIVATING FACTOR; CARBONATE DEHYDRATASE; CD20 ANTIGEN; DELTA 4 B CELL ACTIVATING FACTOR; EPRATUZUMAB; FC RECEPTOR; FC RECEPTOR IIIB; GRANULOCYTE COLONY STIMULATING FACTOR; HYDROCORTISONE; IMMUNOGLOBULIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN F(AB) FRAGMENT; INFLIXIMAB; INTERLEUKIN 6; PHOSPHATASE; PROTEIN BAX; RHEUMATOID FACTOR; STEROID 21 MONOOXYGENASE; TOLL LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; BIOLOGICAL PRODUCT;

ADRENAL INSUFFICIENCY; ANTIGEN ANTIBODY COMPLEX; AUTOIMMUNE DISEASE; B LYMPHOCYTE; DISEASE ACTIVITY; DOWN REGULATION; EDITORIAL; ENZYME LINKED IMMUNOSORBENT ASSAY; GOLGI COMPLEX; HUMAN; HUMORAL IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNODIFFUSION; INNATE IMMUNITY; KIDNEY TUBULE ACIDOSIS; KNOCKOUT MOUSE; LYMPHOCYTIC INFILTRATION; LYMPHOMA; MEMORY CELL; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; POLYCLONAL ACTIVATION; PRIMARY BILIARY CIRRHOSIS; PROGNOSIS; RNA BINDING; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; TH17 CELL; THYROIDITIS; VISUAL ANALOG SCALE; WESTERN BLOTTING; IMMUNOLOGY; SJOGREN'S SYNDROME;

AUTOANTIBODIES; B-LYMPHOCYTES; BIOLOGICAL PRODUCTS; HUMANS; PROGNOSIS; SJOGREN'S SYNDROME;

EID: 84924488969     PISSN: 1297319X     EISSN: 17787254     Source Type: Journal    
DOI: 10.1016/j.jbspin.2014.10.018     Document Type: Editorial

References (20)

1. Moutsopoulos H.M. Sjogren's syndrome: a forty-year scientific journey. J Autoimmun 2014, 51:1-9.
2. Jonsson R., Bolstad A.I., Brokstad K.A., et al. Sjogren's syndrome--a plethora of clinical and immunological phenotypes with a complex genetic background. Ann N Y Acad Sci 2007, 1108:433-447.
3. Scofield A.K., Radfar L., Ice J.A., et al. Relation of sensory peripheral neuropathy in Sjogren syndrome to anti-Ro/SSA. J Clin Rheumatol 2012, 18:290-293.
4. Youinou P. Sjogren's syndrome: a quintessential B cell-induced autoimmune disease. Joint Bone Spine 2008, 75:1-2.
5. Jonsson R., Theander E., Sjostrom B., et al. Autoantibodies present before symptom onset in primary Sjogren syndrome. JAMA 2013, 310:1854-1855.
6. Youinou P., Durand V., Renaudineau Y., et al. Pathogenic effects of anti-Fc gamma receptor IIIb (CD16) on polymorphonuclear neutrophils in non-organ-specific autoimmune diseases. Autoimmun Rev 2002, 1:13-19.
7. Puga I., Cols M., Barra C.M., et al. B cell-helper neutrophils stimulate the diversification and production of immunoglobulin in the marginal zone of the spleen. Nature Immunol 2012, 13:170-180.
8. Le Pottier L., Devauchelle V., Fautrel A., et al. Ectopic germinal centers are rare in Sjogren's syndrome salivary glands and do not exclude autoreactive B cells. J Immunol 2009, 182:3540-3547.
9. Roberts M.E., Kaminski D., Jenks S.A., et al. Primary Sjogren's syndrome is characterized by distinct phenotypic and transcriptional profiles of IgD+ unswitched memory B cells. Arthritis Rheumatol 2014, 66:2558-2569.
10. Guerrier T., Youinou P., Pers J.O., et al. TLR9 drives the development of transitional B cells towards the marginal zone pathway and promotes autoimmunity. J Autoimmun 2012, 39:173-179.
11. Pers J.O., Daridon C., Devauchelle V., et al. BAFF overexpression is associated with autoantibody production in autoimmune diseases. Ann N Y Acad Sci 2005, 1050:34-39.
12. Mariette X., Ravaud P., Steinfeld S., et al. Inefficacy of infliximab in primary Sjogren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjogren's Syndrome (TRIPSS). Arthritis Rheumatol 2004, 50:1270-1276.
13. Stohl W. Systemic lupus erythematosus: a blissless disease of too much BLyS (B lymphocyte stimulator) protein. Curr Opinion Rheumatol 2002, 14:522-528.
14. Maini R.N., Taylor P.C., Szechinski J., et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheumatol 2006, 54:2817-2829.
15. Pijpe J., van Imhoff G.W., Spijkervet F.K., et al. Rituximab treatment in patients with primary Sjogren's syndrome: an open-label phase II study. Arthritis Rheumatol 2005, 52:2740-2750.
16. Pers J.O., Devauchelle V., Daridon C., et al. BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sjogren's syndrome. Arthritis Rheumatol 2007, 56:1464-1477.
17. Devauchelle-Pensec V., Mariette X., Jousse-Joulin S., et al. Treatment of primary Sjogren syndrome with rituximab: a randomized trial. Ann Internal Med 2014, 160:233-242.
18. Steinfeld S.D., Tant L., Burmester G.R., et al. Epratuzumab (humanised anti-CD22 antibody) in primary Sjogren's syndrome: an open-label phase I/II study. Arthritis Res Ther 2006, 8:R129.
19. Seite J.F., Guerrier T., Cornec D., et al. TLR9 responses of B cells are repressed by intravenous immunoglobulin through the recruitment of phosphatase. J Autoimmun 2011, 37:190-197.
20. Seite J.F., Goutsmedt C., Youinou P., et al. Intravenous immunoglobulin induces a functional silencing program similar to anergy in human B cells. J Allerg Clin Immunol 2014, 133:181-1890.